10.4 Research Governance, Institutional Review Boards (IRB) & Scientific Integrity

10.4 Research Governance, Institutional Review Boards (IRB) & Scientific Integrity

To lead academic medical centers and community health systems effectively, the nurse executive must master the philosophical foundations of research ethics, federal regulatory classifications, scientific misconduct management, and the operational boundaries between research and quality improvement.

---

Historical Foundations & The Belmont Report

Modern research ethics arose in response to egregious historical atrocities committed in the name of biomedical science. The Nuremberg Code (1947) was drafted following the horrific human experimentation conducted by Nazi physicians during World War II, establishing that voluntary, informed consent is absolutely essential. Decades later, public revelation of the United States Public Health Service Syphilis Study at Tuskegee (1932–1972)—in which impoverished African American men were deliberately misled, denied penicillin therapy, and observed for long-term syphilis pathology—galvanized federal intervention.

Congress passed the National Research Act of 1974, establishing the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. In 1979, the Commission published The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, which remains the cornerstone of federal research governance.

+-------------------------------------------------------------------------+
|                   THE BELMONT REPORT ETHICAL TRIAD                      |
|                                                                         |
|   1. RESPECT FOR PERSONS  -> Autonomy & Voluntariness                   |
|      * Acknowledge personal autonomy of moral agents                    |
|      * Provide additional protections for vulnerable populations        |
|      * Operationalized via rigorous, voluntary INFORMED CONSENT         |
|                                                                         |
|   2. BENEFICENCE          -> Maximize Benefits & Minimize Harms         |
|      * Obligation to 'do no harm' and maximize potential goods          |
|      * Systematic, objective assessment of risk/benefit ratios          |
|      * Operationalized via RESEARCH PROTOCOL RISK MANAGEMENT            |
|                                                                         |
|   3. JUSTICE              -> Fairness in Distribution                   |
|      * Fair selection of research subjects without bias                 |
|      * Equitable distribution of research burdens and benefits          |
|      * Operationalized via INCLUSIVE, NON-EXPLOITATIVE SAMPLING         |
+-------------------------------------------------------------------------+

Application of Belmont Principles

• Respect for Persons: Requires that individuals be treated as autonomous agents capable of deciding whether to participate in research. For individuals with diminished autonomy (e.g., children, prisoners, individuals with cognitive impairments, or critically ill patients), intensive protective safeguards must be mandated. Informed consent must include full disclosure of study aims, procedures, foreseeable risks, potential benefits, alternatives, voluntary participation, and the absolute right to withdraw at any time without penalty.
• Beneficence: Investigators must systematically assess risks (physical, psychological, sociological, legal, and economic) and take proactive steps to minimize them. Research is ethically justifiable only if the anticipated benefits to the subject or the generalizable societal knowledge clearly outweigh the potential risks.
• Justice: Concerns who bears the burdens of research versus who reaps its benefits. The Belmont Report explicitly prohibits selecting research subjects based on convenience, poverty, racial marginalization, or institutionalization (such as selecting prisoners or Medicaid patients to test dangerous procedures whose benefits will accrue exclusively to affluent populations).

---

Federal Regulatory Architecture: 45 CFR 46 (The Common Rule)

The Belmont Report's ethical principles were codified into federal statutory regulation under Title 45 of the Code of Federal Regulations, Part 46 (45 CFR 46), known as The Common Rule. Overseen by the HHS Office for Human Research Protections (OHRP), the Common Rule has been formally adopted by 20 federal departments and agencies funding human subjects research (e.g., NIH, CDC, VA, DOD).

Specialized Subparts for Vulnerable Populations

In addition to general requirements (Subpart A), 45 CFR 46 establishes explicit, heightened protections for vulnerable groups:

• Subpart B: Additional Protections for Pregnant Women, Human Fetuses, and Neonates Involved in Research;
• Subpart C: Additional Protections Pertaining to Biomedical and Behavioral Research Involving Prisoners (strictly limiting research to conditions affecting prisoners as a class);
• Subpart D: Additional Protections for Children Involved as Subjects in Research (mandating parental permission and child assent calibrated to developmental maturity).

Key Provisions of the Revised Common Rule

The 2018 Revised Common Rule modernized research governance by requiring:

• Broad Consent: Establishing regulatory standards for obtaining prospective, broad consent for the secondary storage and research use of identifiable biospecimens and data;
• Single IRB (sIRB) Mandate: Mandating that multi-institution cooperative research studies located in the United States utilize a single IRB of record to streamline oversight and eliminate duplicative reviews;
• Posting of Informed Consent Forms: Mandating that for federally funded clinical trials, one completed, IRB-approved informed consent form must be posted on a publicly available federal website (such as ClinicalTrials.gov) after trial recruitment closes.

---

Institutional Review Board (IRB) Oversight & Levels of Review

An Institutional Review Board (IRB) is an administrative body established to protect the rights, safety, and welfare of human subjects recruited to participate in research activities conducted under the auspices of the institution.

IRB Composition Mandates

Under 45 CFR § 46.107, an IRB must consist of:

• At least five members with diverse backgrounds, professional training, and demographic representation;
• At least one member whose primary concerns are scientific (e.g., physician, nurse scientist, pharmacologist);
• At least one member whose primary concerns are non-scientific (e.g., ethicist, attorney, chaplain);
• At least one member who is completely unaffiliated with the institution and not part of the immediate family of an affiliated member (representing community interests);
• Mandatory recusal: No IRB member may participate in the initial or continuing review of any project in which the member has a conflicting financial or professional interest.

+-------------------------------------------------------------------------+
|                    THE THREE TIERS OF IRB REVIEW                        |
|                                                                         |
|   [EXEMPT REVIEW]                                                       |
|   * Minimal risk; falls under 8 specific federal regulatory categories  |
|   * Examples: Anonymous surveys, educational tests, secondary analysis  |
|     of existing de-identified data, benign behavioral interventions     |
|   * Evaluated by IRB chair or designated compliance officer (NOT self!) |
|                                                                         |
|   [EXPEDITED REVIEW]                                                    |
|   * No more than minimal risk; falls into specific federal categories   |
|   * Examples: Routine blood draws within volume limits, non-invasive    |
|     biological sensors, voice/digital recordings, focus groups          |
|   * Evaluated by IRB chair or single experienced voting member          |
|                                                                         |
|   [FULL BOARD / CONVENED REVIEW]                                        |
|   * Greater than minimal risk (and some vulnerable-population studies) |
|   * Examples: Investigational new drugs/devices (IND/IDE), invasive     |
|     biopsies, clinical trials on children/prisoners/ICU patients       |
|   * Evaluated by a convened quorum at a formal, minuted IRB meeting    |
+-------------------------------------------------------------------------+

---

Scientific Integrity & Managing Research Misconduct

Nurse executives are responsible for protecting the scientific integrity of all research conducted within the health system. Federal regulations promulgated by the Public Health Service (PHS) and HHS Office of Research Integrity (ORI) under 42 CFR Part 93 establish strict definitions and procedures for addressing research misconduct.

The Federal Definition of Research Misconduct

Research misconduct is formally defined as Fabrication, Falsification, or Plagiarism (FFP) in proposing, performing, or reviewing research, or in reporting research results:

1. Fabrication: Making up data or results and recording or reporting them;
2. Falsification: Manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record;
3. Plagiarism: The appropriation of another person's ideas, processes, results, or words without giving appropriate credit.

Critical Regulatory Exclusion: Research misconduct does not include honest error or differences of opinion. To establish a finding of research misconduct, there must be a significant departure from accepted practices of the relevant research community, committed intentionally, knowingly, or recklessly, proven by a preponderance of the evidence.

The Institutional Misconduct Response Procedure

When an allegation of scientific misconduct surfaces, the institution must follow a multi-stage procedural sequence:

• Assessment: A documented preliminary determination by the research integrity officer whether the allegation falls within the definition of research misconduct and is specific and credible enough to warrant an inquiry.
• Inquiry: A confidential fact-finding review to determine whether an investigation is warranted. Under ORI's revised rule (applying to allegations received on or after January 1, 2026) the inquiry generally must be completed within 90 days (previously 60).
• Investigation: A comprehensive investigation by a committee with appropriate scientific expertise, generally completed within 180 days (previously 120), examining research records, notebooks, audit logs, code and raw data.
• Findings and Reporting: The institution reports its investigation to the HHS Office of Research Integrity (ORI), which makes federal findings and may impose administrative actions (such as supervision requirements or debarment); the institution may separately impose its own sanctions and correct the research record, for example by requesting retractions.

---

Differentiating Research, Quality Improvement (QI) & Evidence-Based Practice (EBP)

One of the most complex governance dilemmas confronting executive nurse leaders is differentiating between Clinical Research, Quality Improvement (QI), and Evidence-Based Practice (EBP). While all three methodologies utilize data, their fundamental intent, regulatory oversight, and ethical frameworks diverge significantly.

+-------------------------------------------------------------------------+
|               QI vs. EBP vs. CLINICAL RESEARCH COMPARISON               |
|                                                                         |
|   [CLINICAL RESEARCH]                                                   |
|   * Intent: Generate generalizable new scientific knowledge.            |
|   * Scope: Broad, universal application across populations.             |
|   * Design: Experimental, control groups, randomized trials.            |
|   * Oversight: Mandatory IRB oversight under 45 CFR 46.                 |
|                                                                         |
|   [EVIDENCE-BASED PRACTICE (EBP)]                                       |
|   * Intent: Translate existing external scientific evidence to care.    |
|   * Scope: Unit- or hospital-level clinical workflow improvement.       |
|   * Design: Synthesis of literature, pilot testing, practice change.    |
|   * Oversight: Clinical Practice Council; usually exempt/non-research.   |
|                                                                         |
|   [QUALITY IMPROVEMENT (QI)]                                            |
|   * Intent: Improve specific, local operational process or outcome.     |
|   * Scope: Internal healthcare microsystem (specific unit or clinic).   |
|   * Design: Rapid PDSA cycles, Lean/Six Sigma, run charts.              |
|   * Oversight: Quality Governance; non-human subjects research.         |
+-------------------------------------------------------------------------+

When Does QI Cross the Threshold into Research?

A project begins as Quality Improvement when the intent is strictly internal operational optimization (e.g., standardizing a central line dressing change kit to reduce CLABSI on a surgical unit). However, the project crosses into clinical research requiring IRB review if:

• The methodology involves withholding an established standard of care from a control group to evaluate comparative effectiveness;
• Patients are subjected to experimental, unproven interventions carrying incremental physiological or psychological risks;
• The primary aim is explicitly designed to generate generalizable scientific theory rather than local operational improvement.

---

Executive Sponsorship of Nursing Inquiry & Magnet® Alignment

To build a premier clinical enterprise, the Chief Nursing Officer must actively sponsor and resource nursing inquiry across all operational service lines. Under the American Nurses Credentialing Center (ANCC) Magnet Recognition® model, the component New Knowledge, Innovations, and Improvements (NKII) mandates that health systems demonstrate empirical evidence of nurse-led research and widespread EBP dissemination.

PhD and DNP Collaboration Architecture

High-performing nurse executives resolve professional silos by pairing Doctor of Philosophy (PhD) nurse scientists with Doctor of Nursing Practice (DNP) executive and clinical leaders:

• PhD Nurse Scientists: Specialize in scientific discovery, advanced experimental design, external federal grant procurement (e.g., NIH/NINR R01 grants), and generating generalizable nursing science.
• DNP Clinical Leaders: Specialize in implementation science, systems leadership, translation of empirical research into bedside clinical pathways, and leading robust QI initiatives.
• The Nursing Research Council (NRC): The CNO establishes an institutional NRC that reviews proposed nursing inquiry, provides biostatistical support, navigates IRB submissions, awards intramural seed grants, and mentors frontline staff nurses in presenting podium and poster abstracts at national symposia.